← back to search

Bo Ma

University of Alabama at Birmingham · US
Area of research
Molecular Biology · Pathology and Forensic Medicine
Research interest
Research interests include Medicine, Dabrafenib, Glioma, Melanoma, Tolerability, and Adverse effect.
h-index
citations
1,442
works
5
NIH funding
primary concept
email

Recent publications

Vitamin B12 Ameliorates the Pathological Phenotypes of Multiple Parkinson’s Disease Models by Alleviating Oxidative Stress
Antioxidants 2023cited by 16position: middledoi
Rational Design of a Two‐Photon Fluorogenic Probe for Visualizing Monoamine Oxidase A Activity in Human Glioma Tissues
Angewandte Chemie International Edition 2020cited by 89position: middledoi
α-Arbutin Protects Against Parkinson’s Disease-Associated Mitochondrial Dysfunction In Vitro and In Vivo
NeuroMolecular Medicine 2019cited by 58position: middledoi
BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i> -Mutant Thyroid Cancer
Thyroid 2014cited by 229position: middledoi
Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)
Clinical Cancer Research 2014cited by 65position: middledoi
A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
Clinical Cancer Research 2013cited by 126position: middledoi
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
The Lancet 2012cited by 933position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Chengwu Zhang · National University of Singapore3 papers (2019–2023)C. Martin Curtis · University of Alabama at Birmingham3 papers (2012–2014)Razelle Kurzrock · Froedtert Hospital3 papers (2012–2014)Naidi Yang · National University of Singapore3 papers (2019–2023)Gerald S. Falchook · Sarah Cannon Research Institute3 papers (2012–2014)Lin Li · Guangzhou Medical University3 papers (2019–2023)Changmin Yu · National University of Singapore2 papers (2020–2023)Qiong Wu · Ministry of Education of the People's Republic of China2 papers (2019–2020)Jeffrey R. Infante · Janssen (United States)2 papers (2012–2014)Samuel C. Blackman · Google (United States)2 papers (2012–2014)Chenqi Xin · Nanjing Tech University2 papers (2019–2023)Kevin B. Kim · Ludwig-Maximilians-Universität München2 papers (2012–2014)Michael P. Brown · Royal Adelaide Hospital2 papers (2012–2014) · 2 papers (2012–2014)Omid Hamid · University Hospital Münster2 papers (2012–2014)Anna C. Pavlick · Cornell University2 papers (2012–2014)Steven O’Day · Agenus (United States)2 papers (2012–2014)Peter F. Lebowitz · New York University2 papers (2012–2014)Richard Kefford · Macquarie University2 papers (2012–2014)Georgina V. Long · ARC Centre of Excellence in Synthetic Biology2 papers (2012–2014)